Kornimate/medical-research-clean huggingface dataset:
comparative effects of visual and pressure biofeedback in symptomatic forward head posture.

Conditions: Forward Head Posture

Summary: this study aims to determined the comparative effect of visual and pressure biofeedback on pain,disability and range of motion in young and middle aged adults diagnosed with forward head posture.

forward head posture describes the shifting of the head forward with the chin poking out. it is caused by increased flexion of the lower cervical spine and upper thoracic. forward head posture is the most frequently observed postural deviations and is said to be associated with shortening of posterior cervical extensors and weakening of the anterior deep cervical flexors. in this randomized control trial participants showing forward head posture will be randomly assigned into two intervention groups. 28 subjects were divided equally into two groups 14 each containing both genders. group a (experimental group) will be given isometric strengthening and stretching training guided pressure biofeedback. group b (experimental group) will be given isometric strengthening and stretching training of deep cervical flexor (dcf) muscle guided through visual biofeedback . each participant will be receive a total of twelve treatment sessions over a four-week period. the efficacy of the interventions will be assessed at the beginning (first session) and conclusion (last session) of the treatment period. the assessment will encompass various outcome measures. pain intensity will be evaluated using the numeric pain rating scale (nprs), while disability levels will be measured using the neck disability index (ndi). the cervical active range of motions (caroms) will be assessed by goniometry. finally, the visual feedback referred as indicator of measuring forward head posture by evaluating these outcome measures insights will be gained into the impact of the interventions on the participants' symptoms and postural alignment through light. the randomized design of the trial provide valuable information to healthcare professionals on how to manage symptomatic forward head posture and may contribute to the development of future research in this area.

Eligibility criteria:
inclusion criteria: 1. participants would be complaining of neck pain as a primary complain and age of 20- 35 year was recruited in the study . 2 . male and female both gender are included in the study. 3. patient with craniovertebral angle (cva)\<53 degree were included in the study . 4. score more than 3 on nprs and more than 10 on ndi. exclusion criteria: participant failing to fall in this category would be excluded of the study. 1. neurogenic findings like cervical trauma, myopathy, vestibular pathology, dizziness, visual problem, spinal fracture, dislocation and hypertension will not include in the study. 2. history of sever metabolic diseases. 3. history of recurrent surgery in upper thoracic and lumber vertebrae 4. history of recent fractures in shoulder and neck region. 5. history of tumor. -

Keywords: fhp
randomized-controlled trial of preoperative inspiratory muscle training on postoperative complications

Conditions: Postoperative Complications; Breathing Exercises; Preoperative Period

Summary: rehabilitation strategies after abdominal surgery enhance recovery and improve outcome. a cornerstone of rehabilitation is respiratory physiotherapy with inspiratory muscle training to enhance pulmonary function. prehabilitation is the process of enhancing functional capacity before surgery in order to compensate for the stress of surgery and postoperative recovery. there is growing interest in deploying pre-habilitation interventions prior to surgery. the aim of this study is to assess the impact of preoperative inspiratory muscle training on postoperative overall morbidity. the question is, whether inspiratory muscle training prior to elective abdominal surgery reduces the number of postoperative complications and their severity grade.

inspira is a prospective randomized-controlled single-center trial, non-blinded the aim of this study is to assess the impact of preoperative inspiratory muscle training on postoperative overall morbidity. the question is, whether inspiratory muscle training prior to elective abdominal surgery reduces the number of post-operative complications and their severity grade. furthermore, the impact of preoperative inspiratory muscle training on postoperative physiotherapeutic performance as surrogate of convalescence is assessed, too. patients will be instructed by physiotherapists to perform inspiratory muscle training containing of 30 breaths twice a day for 14-18 days before surgery using power®breathe khp2. primary outcome is comprehensive complication index (cci) at 90 days after surgery. the cci expresses morbidity on a con-tinuous numeric scale from 0 (no complication) to 100 (death) by weighing all postoperative complications according to the clavien-dindo classification for their respective severity.

Eligibility criteria:
inclusion criteria: * informed consent as documented by signature (appendix patient informed consent form) * planned abdominal surgery with planned duration \>2hours (disease localization: upper vs. lower gastro intestinal, hpb, hernia, others) * planned surgery at least two weeks after inclusion at outpatient clinic * male and female patient over 18 years exclusion criteria: * inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, of the participant * known or suspected non-compliance, drug or alcohol abuse, * previous enrolment into the current study * participation in another study with inspiratory muscle training within 30 days preceding or during this study

Keywords: inspiratory muscle training cci postoperative complications prehabilitation preoperative respiratory training
cardiovascular variability and heart rate arousal response in idiopathic hypersomnia

Conditions: Narcolepsy; Cataplexy

Summary: autonomic nervous system dysfunction has been described in narcolepsy with cataplexy affecting the sympathetic function. in this study the investigators analyzed whether altered diurnal and nocturnal cardiovascular control is present in idiopathic hypersomnia. drug-free patients diagnosed with idiopathic hypersomnia and age-matched controls were included. clinical data, 24-h polysomnography, heart rate variability and the heart rate response to spontaneous arousal are analyzed.


Eligibility criteria:
inclusion criteria: idiopathic hypersomnia patients * idiopathic hypersomnia diagnosis * complaints of excessive daytime sleepiness for \>1 year * a night-time length \>10 h for 3 weeks before polysomnography as assessed by a sleep diary inclusion criteria: no idiopathic hypersomnia patients * no sleep complaints and excessive daytime sleepiness (epworth sleep questionnaire score \<10 exclusion criteria (both): * narcolepsy-cataplexy * sleep irregularities and sleep deprivation symptoms * lack of neurological or psychiatric diseases * upper airway resistance syndrome * periodic limbs movements * cerebral lesion * medication or drinks affecting sleep and wake state

Keywords: idiopathic hypersomnia heart rate variability parasympathetic activity autonomic arousal response
retro-prospective observational study on risk of progression in cp-cml patients eligible for tki discontinuation

Conditions: Chronic Myeloid Leukemia

Summary: the purpose of this study is to investigate the safety profile of tki discontinuation in clinical practice, with particular regard on the risk of progression after treatment discontinuation.

this study will enroll approximately 3000 cp-cml patients that must have a history of at least 4 years of tki treatment and at least 18 months of dmr. events developing in patients after the end of discontinuation and tki resumption will be considered as linked to the discontinuation if they will develop within 36 months from the end of discontinuation. this rule will apply also to subsequent td attempts. in case of a second or subsequent discontinuation attempt after the failure of a previous one (for molecular relapse), patients must have re-achieved a dmr with tki therapy resumption and must keep dmr for at least 18 months before another td. collection of data will be retrospective and prospective, as each center will collect the data for 24 months. patients who discontinued before the opening of this study will contribute to the retrospective cohort, while those who will discontinue after it will contribute to the prospective cohort. patients who discontinued before the opening of this study but will continue their discontinuation after it, will contribute to both cohorts. for patients prospectively recruited, monitoring of disease status will be performed to assess the maintenance of the molecular remission during the study period. patients with an atypical bcr-abl1 fusion gene, which does not allow the use of q-rt-pcr, will be monitored by qualitative pcr and will be analyzed separately. for these patients, negativity of nested qualitative rt-pcr will be considered a surrogate of dmr of patients monitored by q-rt-pcr, while loss of negativity of first-round qualitative pcr will be considered a surrogate of loss of mmr (i.e. molecular relapse). accordingly, for patients monitored by qualitative pcr, tki resumption after td will be provided in case of a new positivity of first-round pcr. .

Eligibility criteria:
inclusion criteria: 1. signed and dated irb/iec-approved informed consent for the prospective cohort patients. 2. age \>= 18 years. 3. male or female patients with cml diagnosed in chronic phase (cp). 4. at least 4 years of tki treatment. 5. at least 18 months of dmr. exclusion criteria: * allogeneic hematopoietic stem cell transplantation. * cml diagnosed in ap or bc
the effect of remote ischemic preconditioning on kidney function in patients undergoing partial nephrectomy

Conditions: Renal Neoplasm; Renal Injury

Summary: this study is intended to evaluate the renal protective effect of remote ischemic preconditioning (ripc) in patients undergoing partial nephrectomy. half of the enrolled subjects will receive 4 cycles of brief ischemia on the upper arm after anesthesia induction and prior to the surgery, while the other half will not receive this treatment as a control group.

remote ischemic preconditioning (ripc) is the concept of mitigating ischemia-reperfusion injury to target organs by a brief episode of ischemia-reperfusion of the limb. the protective effect of ripc on major organs has been demonstrated in an animal study, but its clinical efficacy has not yet been established. the kidney is a typical organ vulnerable to ischemic injury, and the renal protective effect of ripc can be expected. there have been many reports of renal protective effects of ripc in cardiac and vascular surgery. on the other hand, few studies have investigated the effect of ripc during partial nephrectomy in which ischemia-reperfusion injury can occur during the surgery. in this study, the investigators will evaluate the effect of ripc in patients undergoing partial nephrectomy to prevent renal impairment and improve the prognosis after the surgery.

Eligibility criteria:
inclusion criteria: * adult patients scheduled to undergo open, laparoscopic, or robot-assisted laparoscopic partial nephrectomy * normal contralateral renal function was defined as split renal function of \>40% as determined by preoperative tc-99m diethylenetriamine pentaacetic acid (dtpa) kidney scan * written informed consent exclusion criteria: * peripheral vascular disease involving upper extremities or lower extremities * severe cardiopulmonary diseases (valvular or ischemic heart disease, heart failure, chronic obstructive pulmonary disease) * hepatic failure, renal failure

Keywords: remote ischemic preconditioning partial nephrectomy acute kidney injury
n-acetylcysteine for adolescent alcohol use disorder

Conditions: Alcohol Use Disorder

Summary: this is a 8-week randomized, placebo-controlled trial testing the effects of n-acetylcysteine (nac), on a platform of weekly evidence-based brief alcohol intervention for 120 adolescents with alcohol use disorder (aud). the primary efficacy endpoint is reduction in alcohol use (total standard drinks), compared between nac and placebo groups.

adolescence is a critical developmental stage involving marked elevation in alcohol initiation, progression to aud, and development of significant, lasting adverse outcomes from use. effective treatments must be developed for aud in this especially vulnerable age range. the identification of a well-tolerated, effective pharmacological treatment would represent a significant advance and could yield tremendous public health impact. the proposed trial will provide critical data to evaluate nac as a highly promising pharmacotherapy for adolescent aud, and regardless of nac versus placebo outcomes will provide key methodological guidance for future randomized controlled trials of pharmacotherapies for adolescent aud. randomized participants will be provided and instructed to take their assigned medication at 1200 mg twice daily, in approximately twelve-hour intervals.

Eligibility criteria:
inclusion criteria: 1. subject is 13-25 2. must be able to understand the study and provide written informed consent (for participants under 18 years old, a parent/legal guardian must be able to provide consent and the participant must be able to provide assent). 3. current moderate to heavy drinker by established adolescent criteria 4. meet criteria for alcohol use disorder 5. females must agree to use appropriate birth control methods during study participation: oral contraceptives, contraceptive patch, barrier (diaphragm or condom), levonorgestrel implant, medroxyprogesterone acetate, complete abstinence from sexual intercourse, or hormonal contraceptive vaginal ring exclusion criteria: 1. score \>10 on the clinical institute withdrawal assessment for alcohol 2. allergy or intolerance to n-acetylcysteine 3. females who are pregnant, contemplating pregnancy or lactating over the next 6 months 4. current use of n-acetylcysteine or any supplement containing n-acetylcysteine (must agree not to take any such supplement throughout study participation) 5. current enrollment in treatment for alcohol use disorder or expectation of other treatment during protocol participation 6. any other medical or psychiatric condition or other significant concern that in the investigator's opinion would impact participant safety or compliance with study instructions, or potentially cofound the interpretation of findings

Keywords: alcohol youth adolescent pharmacotherapy medication n-acetylcysteine
early and late prognosis in patients with guillain-barre syndrome

Conditions: Guillain-Barre Syndrome

Summary: the goal of this observational study is to explore significant indicators to predict the early prognosis and late prognosis in patients with guillain-barre syndrome.

this is a multicenter study(approximately three) with over 450 subjects.clinical data were collected by consulting the patient's electronic history. the data included demographic information, blood biochemical markers, clinical characteristics and electromyography. all participants provided their written informed consent to participate in this study.

Eligibility criteria:
inclusion criteria: * patients fulfilled clinical, biological, and electrophysiology criteria for guillain-barre syndrome. exclusion criteria: * nonidiopathic guillain-barre syndrome and miller fisher syndrome

Keywords: guillain-barre syndrome prognosis
increasing physical activity among breast cancer survivors with depression

Conditions: Depression; Physical Activity; Breast Cancer

Summary: pilot study to assess a multi-component intervention to increase physical activity among breast cancer survivors with depression.

the research project is a pilot study to assess the effects of a multi-component intervention in increasing physical activity among breast cancer survivors with depression. individuals meeting inclusion/exclusion criteria will be enrolled in the 12-week intervention with a 6 month follow up. intervention components will include print-based education, self-monitoring, active living counseling, and facility access. blood samples will be collected at baseline. assessments (anxiety, stress, sleep) and sample collection will also occur at 3 time points during the intervention (weeks 7, 13, and 25). changes in physical activity will be assessed using fitbits to measure weekly minutes of moderate/vigorous activity.

Eligibility criteria:
inclusion criteria: * positive depression screen (phq-9) or current antidepressant treatment * report \<150 minutes of weekly moderate-to-vigorous physical activity (mvpa) on the gpaq * physically able to engage in physical activity * written and verbal fluency in english exclusion criteria: * medical condition contraindicating physical activity participation * recurrence of breast cancer * ductal carcinoma in situ (dcis) diagnosis * cognitively unable to give informed consent * non-english speaking
effect of duloxetine on opioid use after total knee arthroplasty

Conditions: Joint Disease; Pain, Acute; Pain, Chronic

Summary: post-discharge pain after total knee arthroplasty remains problematic; many patients have excessive pain at the 2 week time point (and often thereafter). reduction in opioid use has become a national goal, due to the 'epidemic' in opioid misuse. in addition to enrolling non-opioid users, we will enroll up to 15 chronic opioid users.


Eligibility criteria:
inclusion criteria: * age 25 to 75 years * planned use of regional anesthesia * ability to follow study protocol * english speaking (primary outcome obtained via telephone call and secondary outcomes include questionnaires validated in english only) * patients planning on being discharged home or to a rehabilitation center that has agreed to participate exclusion criteria: * current use of duloxetine or other snris, ssris, maois, tricyclic antidepressants, triptans (sumatriptan, rizatriptan, naratriptan, eletriptan, almotriptan, frovatriptan), lithium, buspirone, st. john's wort * hepatic insufficiency o hepatoxicity is reported as a side effect of duloxetine. "median time to detection of transaminase elevation was about two months" (package insert 5.2 * renal insufficiency (esrd, hd, estimated creatinine clearance \< 50 ml/min) * severe cri may impair duloxetine clearance * clcr=\[(140-age (years)\] x weight (kg)x0.85 (for female patients)/\[72xserum creatinine (mg/dl)\] * patients younger than 25 years old and older than 75 * patients intending to receive general anesthesia * allergy or intolerance to one of the study medications * patients with an asa of iv * chronic gabapentin/pregabalin use (regular use for longer than 3 months) * patients with major prior ipsilateral open knee surgery. * chronic opioid use (taking opioids for longer than 3 months) * however, patients using chronic opioids may enroll in a parallel pilot study entitled 'effect of duloxetine on opioid use after total knee athroplasty among patients exposed to opioids- a pilot study'. the chronic opioid users will be allowed to continue their customary analgesics. the pilot study is otherwise identical to the main study. * this study will enroll up to 15 chronic opioid users. after that, all chronic opioid users are excluded.
development of preclinical models derived from tumors with a molecular abnormality of interest to test their sensitivity to new anti-tumor therapies.

Conditions: Neoplasm Malignant

Summary: this study aims to collect tumor samples from patients carrying a mutation of interest to develop a cell culture technique for "spheroids. the goal is to use these spheroids to model responses to anticancer treatments. various therapeutic molecules can be tested on these spheroids, enabling the evaluation of the potential of new molecules or the activity of existing ones specifically on the tumor (bearing the mutation of interest) from which the spheroid was developed. tumor samples will be collected as part of biopsies or surgeries conducted during routine patient care.


Eligibility criteria:
inclusion criteria: * age 18 years or older. * patient for whom at least one mutation deemed of interest by the investigator has been identified. * patient with a malignant tumor at a locally advanced or metastatic stage, for whom a tissue tumor sample (via surgery, radiology, or endoscopy) is scheduled as part of their standard care. * tumor volume deemed sufficient by the physician to ensure an adequate amount of material for analysis by the pathologist and the transfer of a part of the tumor sample to the laboratory of translational research in oncology for the study. * inr \< 1.5; platelets \< 50,000/μl. * patient who has been informed of the study and has signed the informed consent form. * patient affiliated with a social security insurance. exclusion criteria: * patient with multiple primary malignant tumors. * patient with a known hiv, hepatitis c, or hepatitis b infection. * patient on: * clopidogrel (hydrogensulfate) or prasugrel (hydrochloride) or ticlopidine (hydrochloride) with no possibility of suspension for 5 days, * low molecular weight heparin with no possibility of dose suspension before the procedure, * fondaparinux with no possibility of suspension, * abciximab with no possibility of suspension for 24 hours and aptt \< 50s and act \< 150s, * eptifibatide or tirofiban hydrochloride monohydrate or argatroban with no possibility of suspension 4 hours before the procedure, * bivalirudin with no possibility of suspension 2-3 hours if crcl \>50 ml/min or 3-5 hours if crcl \<50 ml/min before the procedure, * dabigatran etexilate with no possibility of suspension 2-3 days if crcl \>50 ml/min or 3-5 days if crcl \<50 ml/min before the procedure. * patient considered vulnerable; vulnerable persons are defined in articles l1121-5 to l1121-8: * pregnant women, parturients, and breastfeeding mothers, * individuals deprived of their liberty by a judicial or administrative decision, individuals hospitalized without consent under articles l. 3212-1 and l. 3213-1 who do not fall under the provisions of article l. 1121-8, and individuals admitted to a healthcare or social facility for reasons other than research, * adults under legal protection or unable to express their consent.

Keywords: spheroids preclinic models